We value your privacy
We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.
Clinical Trials
0
0 active
Approvals
344
Total approvals
Agencies
5
Regulatory bodies
Founded
N/A
No trial phase data available
No trial data available
NMPA
National Medical Products Administration
FDA
Food and Drug Administration
244
PHILIPPINES
Philippines FDA
38
SFDA
Saudi Food and Drug Authority
42
NPRA
National Pharmaceutical Regulatory Agency
15
- Gland Pharma Limited secured FDA approval for its generic version of olopatadine hydrochloride 0.7% ophthalmic solution, equivalent to Alcon's Pataday Once Daily Extra Strength. - The over-the-counter eye drops treat ocular itching associated with allergic conjunctivitis and provide 24-hour relief with once-daily dosing. - This approval marks the second generic version of a Pataday formulation to receive FDA clearance, following Glenmark's approval for the 0.2% concentration in 2025. - The company's shares gained 0.99% following the announcement, reflecting investor confidence in Gland Pharma's expanding ophthalmic portfolio.
